Suppr超能文献

晶体停搏液的给药途径与心肌肌钙蛋白I释放

Crystalloid cardioplegia route of delivery and cardiac troponin I release.

作者信息

Chocron S, Alwan K, Toubin G, Clement F, Kaili D, Taberlet C, Cordier A, Etievent J P

机构信息

Department of Thoracic and Cardiovascular Surgery, Saint-Jacques Hospital, Besancon, France.

出版信息

Ann Thorac Surg. 1996 Aug;62(2):481-5.

PMID:8694609
Abstract

BACKGROUND

Cardiac troponin I (CTn I) has been shown to be a marker of myocardial injury. Incomplete distribution of cardioplegic solution may be responsible for injury in jeopardized myocardial areas. The aim of this study was to compare CTn I release with respect to the route of delivery of crystalloid cardioplegia, either antegrade only or initially antegrade followed by retrograde cardioplegia for the remainder of the operation, in patients undergoing elective coronary artery bypass grafting.

METHODS

Sixty patients were randomly assigned to one of two cardioplegia groups. Cardiac troponin I concentrations were measured in serial venous blood samples drawn just before cardiopulmonary bypass and after aortic unclamping at 6, 9, 12, and 24 hours and daily thereafter for 5 days. Analysis of variance with repeated measures was performed to test the effect of route of delivery, coronary disease, collateral circulation, risk of cardioplegia maldistribution, and number of grafts on release of CTn I.

RESULTS

Compared with the antegrade route, the combined route offered no advantage in an unselected group of patients undergoing an elective first cardiac operation and having preserved left ventricular function. The CTn I concentration did not differ between groups for any of the samples considered. In patients with major left main coronary artery stenosis, CTn I release was significantly higher at hour 9 in the antegrade group than in the group with combined delivery.

CONCLUSIONS

A combined route of delivery of crystalloid cardioplegia is beneficial in patients with major stenosis of the left main coronary artery. Cardiac troponin I sensitivity is relevant in this study. Release of CTn I should be useful in determining the best form of myocardial protection for each patient.

摘要

背景

心肌肌钙蛋白I(CTn I)已被证明是心肌损伤的标志物。心脏停搏液分布不完全可能是心肌危险区域损伤的原因。本研究的目的是比较在接受择期冠状动脉旁路移植术的患者中,晶体心脏停搏液仅顺行给药或最初顺行给药随后在手术剩余时间逆行心脏停搏液给药两种方式下CTn I的释放情况。

方法

60例患者被随机分配到两个心脏停搏液组之一。在体外循环前以及主动脉开放后6、9、12和24小时及此后每天直至5天,采集系列静脉血样本测量心肌肌钙蛋白I浓度。采用重复测量方差分析来检验给药途径、冠状动脉疾病、侧支循环、心脏停搏液分布不均风险和移植血管数量对CTn I释放的影响。

结果

与顺行途径相比,在未选择的接受择期首次心脏手术且左心室功能保留的患者组中,联合途径没有优势。在所有考虑的样本中,两组之间的CTn I浓度没有差异。在左主干冠状动脉严重狭窄的患者中,顺行组在第9小时的CTn I释放显著高于联合给药组。

结论

晶体心脏停搏液联合给药途径对左主干冠状动脉严重狭窄的患者有益。本研究中,心肌肌钙蛋白I的敏感性具有相关性。CTn I的释放应有助于确定针对每位患者的最佳心肌保护形式。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验